Compass Therapeutics (NASDAQ:CMPX) Rating Increased to Buy at LADENBURG THALM/SH SH
LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) from a neutral rating to a buy rating in a research report report published on Monday morning, MarketBeat Ratings reports. The firm currently has $5.00 price objective on the stock. A number of other research analysts also recently issued reports on the stock. […]
20 Sep 07:56 · The Markets Daily